See the DrugPatentWatch profile for yervoy

Yervoy, also known as ipilimumab, is a type of immunotherapy used to treat certain types of cancer. It works by stimulating the body's own immune system to fight cancer cells. When comparing Yervoy to other treatments, several factors must be considered, including efficacy, side effects, and cost.

In terms of efficacy, Yervoy has been shown to be effective in treating metastatic melanoma, a type of skin cancer. According to a study published in the New England Journal of Medicine, Yervoy improved overall survival in patients with metastatic melanoma compared to a different treatment [1]. However, Yervoy may not be as effective in treating other types of cancer.

When comparing side effects, Yervoy can cause serious side effects, including immune-mediated adverse reactions, such as enterocolitis, dermatitis, neuropathy, and endocrinopathy [2]. These side effects can be severe and require hospitalization. Other treatments for cancer may have different side effects, so it is essential to consider the potential risks and benefits of each treatment.

In terms of cost, Yervoy is expensive and can cost up to $300,000 for a course of treatment [3]. This can be a significant barrier to access for some patients. Other treatments for cancer may be less expensive, so it is essential to consider the cost when comparing treatments.

It is also worth noting that there are biosimilar versions of Yervoy available in some countries, which may be less expensive than the original drug [4]. However, the availability and cost of biosimilars can vary depending on the country and healthcare system.

In summary, when comparing Yervoy to other treatments, it is essential to consider efficacy, side effects, and cost. While Yervoy has been shown to be effective in treating metastatic melanoma, it can cause serious side effects and is expensive. Other treatments for cancer may have different efficacy, side effects, and cost, so it is essential to consider these factors when making treatment decisions.

Sources:

1. Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., ... & Chiarion-Sileni, V. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. New England Journal of Medicine, 363(8), 711-723.
2. Yervoy (ipilimumab) prescribing information. Bristol-Myers Squibb Company. [Online] Available at: <https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125277s000lbl.pdf>.
3. Howard, D. H., & Keating, G. M. (2014). Cancer drug pricing: value, affordability, and policy options. JAMA oncology, 1(4), 474-479.
4. DrugPatentWatch.com. Ipilimumab (Yervoy) Biosimilars. [Online] Available at: <https://www.drugpatentwatch.com/ipilimumab-yervoy-biosimilars>.